정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1381 | Active, not recruiting | Favipiravir in High-risk COVID-19 Patients | Covid19 | Drug: Favipiravir | Phase 3 | Penang Hospital, Malaysia, Enche' Besar Hajjah Khalsom Hospital, Jasin Hospital, Kepala Batas Hospital, Melaka Hospital, Permai Hospital, The Queen Elizabeth Hospital, Raja Perempuan Zainab II Hospital, Raja Permaisuri Bainun Hospital, Sultanah Aminah Hospital, Sultanah Nur Zahirah Hospital, Sungai Buloh Hospital, Tampin Hospital, Tengku Ampuan Afzan Hospital, Tuanku Fauziah Hospital, Tuanku Jaafar Hospital, Tumpat Hospital, Institute for Clinical Research | OTHER_GOV | 500 | All | 50 Years | Penang General Hospital, George Town, Pulau Pinang, Malaysia |
| 1380 | Not yet recruiting | Favipiravir in Hospitalized COVID-19 Patients | COVID-19 | Drug: Favipiravir Drug: Hydroxychloroquine |
Phase 4 | Shahid Beheshti University of Medical Sciences | OTHER | 40 | All | 18 Years | Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of |
| 1379 | Completed | Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 | Lopinavir/Ritonavir | Drug: Favipiravir Drug: Hydroxychloroquine Drug: Lopinavir / Ritonavir |
Not Applicable | Baqiyatallah Medical Sciences University | OTHER | 40 | All | 16 Years ~ 100 Years | Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of |
| 1378 | Completed | Favipiravir Therapy in Adults With Mild COVID-19 | COVID-19 | Drug: Favipiravir Drug: Placebo |
Phase 3 | King Abdullah International Medical Research Center, Ministry of Health, Saudi Arabia | OTHER | 231 | All | 18 Years ~ 100 Years | Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madinah, Saudi Arabia King Fahad Hospital - Madinah, Al Mad?nah, Saudi Arabia Primary Health Care-Safiyah, Al Mad?nah, Saudi Arabia King Abdullah Medical City - Makkah, Mecca, Saudi Arabia King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia Primary Health Care-Al Mansoura, Riyadh, Saudi Arabia Primary Health Care-Al Urijah, Riyadh, Saudi Arabia |
| 1377 | Completed | Favipiravir vs Hydroxychloroquine vs Control in COVID -19 | COVID-19 | Drug: Hydroxychloroquine Drug: Favipiravir Other: Routine care for COVID-19 patients |
Phase 2 | Royal College of Surgeons in Ireland - Medical University of Bahrain, Ebrahim Khalil Kanoo Community Medical Center, Hereditary blood Disorder Centre - Salmaniya Medical Complex, Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali, Jidhafs COVID-19 Centre, Sitra FICU, Salmaniya Medical Complex- 6th Floor, Salmaniya Medical Complex- Helipad | OTHER | 150 | All | 21 Years | Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain |
| 1376 | Not yet recruiting | Feasibility of Cannabidiol for the Treatment of Long COVID | Long COVID | Drug: Full spectrum cannabidiol dominant medicinal cannabis | Phase 2 | Drug Science, UK, Bod Healthcare Ltd | OTHER | 30 | All | 18 Years ~ 65 Years | |
| 1375 | Recruiting | Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting | Influenza | Drug: Standard-Dose Quadrivalent Influenza Vaccine Drug: High-Dose Quadrivalent Influenza Vaccine |
Phase 2 | Tor Biering-Sørensen, Sanofi Pasteur, a Sanofi Company | OTHER | 40000 | All | 65 Years ~ 79 Years | Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital, Hellerup, Denmark Danske Lægers Vaccinations Service, Søborg, Denmark |